SCHEMBL381229

SCHEMBL381229

CC(=O)[C@]1(O)CC[C@]2(C)[C@H]3CC=C4[C@@H]5CC(C)(C)CC[C@]5(C(=O)O)CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 12/20 0.69
PTPN2 P17706 7/20 0.69
POLB P06746 3/20 0.68
F3 P13726 3/20 0.68
AKR1B10 O60218 3/20 0.68
GPBAR1 Q8TDU6 3/20 0.68
PSMB11 A5LHX3 2/20 0.68
PSMA7 O14818 2/20 0.68
PLA2G1B P04054 2/20 0.68
PTPRC P08575 2/20 0.68
PTPRF P10586 2/20 0.68
PSMB1 P20618 2/20 0.68
CES1 P23141 2/20 0.68
ACP1 P24666 2/20 0.68
PSMA1 P25786 2/20 0.68
PSMA2 P25787 2/20 0.68
PSMA3 P25788 2/20 0.68
PSMA4 P25789 2/20 0.68
PSMB8 P28062 2/20 0.68
PSMB9 P28065 2/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5799296 0.89 PTPN1 (0.73) PTPN1PTPN2POLBF3AKR1B10
SCHEMBL2586364 0.89 PTPN1 (0.73) PTPN1PTPN2POLBF3AKR1B10
SCHEMBL15687736 0.89 PTPN1 (0.68) PTPN1PTPN2POLBF3AKR1B10
SCHEMBL2397201 0.86 PTPN1 (0.68) PTPN1PTPN2POLBF3AKR1B10
SCHEMBL17044616 0.85 PTPN1 (0.60) PTPN1PTPN2POLBF3AKR1B10
SCHEMBL5797472 0.84 PTPN1 (0.72) PTPN1PTPN2POLBF3AKR1B10
SCHEMBL5799434 0.83 PTPN1 (0.72) PTPN1PTPN2POLBF3AKR1B10
SCHEMBL5799378 0.83 PTPN1 (0.72) PTPN1PTPN2POLBF3AKR1B10
SCHEMBL5795816 0.83 PTPN1 (0.72) PTPN1PTPN2POLBF3AKR1B10
SCHEMBL2941690 0.83 PTPN1 (0.69) PTPN1PTPN2POLBAKR1B10GPBAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 317 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118924809-A Traditional Chinese medicine composition for treating and/or preventing osteoporosis and application thereof 江苏大学 2024-11-12 CN claimed
CN-117957014-A ActRII proteins and uses thereof 阿塞勒隆制药公司 2024-04-30 CN claimed
CN-117794562-A ActRII proteins and uses thereof 阿塞勒隆制药公司 2024-03-29 CN claimed
CN-115989035-A ACTRII proteins for the treatment of Pulmonary Arterial Hypertension (PAH) 阿塞勒隆制药公司 2023-04-18 CN claimed
CN-113116955-B Pharmaceutical composition containing plant extracts and application thereof 中国药科大学 2022-10-04 CN claimed
CN-113116955-A Pharmaceutical composition containing plant extracts and application thereof 中国药科大学 2021-07-16 CN claimed
US-20210015830-A1 COMPOSITION FOR INHIBITING REACTIVE OXYGEN SPECIES PRODUCTION SUNTORY HOLDINGS LIMITED (JP) 2021-01-21 US claimed
CN-111743907-A Pharmaceutical composition for preventing and treating AD and application thereof 黑龙江中医药大学 2020-10-09 CN claimed
CN-111565580-A Composition for inhibiting generation of active oxygen 三得利控股株式会社 2020-08-21 CN claimed
CN-102247420-B Preparation method and application of eclipta extract UNIV ZHEJIANG 2013-01-23 CN claimed
CN-102247420-A Preparation method and application of eclipta extract UNIV ZHEJIANG 2011-11-23 CN claimed
CN-101347470-A Glossy privet fruit total triterpenes extract and total phenols extract as well as preparation method thereof RENBING SHI (CN) 2009-01-21 CN claimed
CN-101167788-A Quality control method of 'zhenqi fuzheng' containing glossy privet fruit and radix astragali for strengthening the body resistance traditional Chinese medicine for aeipathia deficiency damage and qi GUIZHOU XINBANG PHARMACY CO LT (CN) 2008-04-30 CN claimed
CN-101053580-A New medical application of traditional Chinese medicine privet and preparation method of its extraction UNIV YANSHAN (CN) 2007-10-17 CN claimed
US-20070014739-A1 Compositions and methods for controlling biofilms and bacterial infections SEQUOIA SCIENCES, INC. 2007-01-18 US claimed
WO-2006019881-A2 COMPOSITIONS AND METHODS FOR CONTROLLING BIOFILMS AND BACTERIAL INFECTIONS ELDRIDGE GARY R (US) 2006-02-23 WO claimed
US-20250195538-A1 BETULIN-CONTAINING BIRCH BARK EXTRACTS AND THEIR FORMULATION AMYRT PHARMACEUTICALS DESIGNATED ACTIVITY COMPANY (IE) 2025-06-19 US disclosed
CN-118105453-B Yang strengthening and hair growing tincture for treating alopecia, and preparation method and application thereof 南京中医药大学 2025-05-09 CN disclosed
CN-1203783-A Preparation of body-building disease-removing bath foam CAI LANQUAN (CN) 1999-01-06 CN disclosed
CN-1185970-A External use medicine for vitiligo SONG SHOUJIN (CN) 1998-07-01 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210015830-A1 COMPOSITION FOR INHIBITING REACTIVE OXYGEN SPECIES PRODUCTION NOX4, CYBB, NOX1 PTPN1 1041/4885PTPN2 905/4885POLB 1803/4885
US-20070014739-A1 Compositions and methods for controlling biofilms and bacterial infections RHOA, ALOX5, BLVRB PTPN1 1158/4885PTPN2 1629/4885POLB 2669/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.